Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

nt and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

                           Financial tables follow



                               InterMune, Inc.
         PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             (unaudited, in thousands, except per share amounts)

                                Three Months Ended      Year Ended
                                      Dec 31              Dec 31
                                   2008      2007      2008      2007
    Revenue, net
      Actimmune                   $6,583    $8,809   $29,880   $53,420
      Collaboration revenue          818       81
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... ... manufacturing of surgical instruments in Orthopedics, announced today the acquisition of Turner ... world's largest provider of surgical instruments to the Spine Industry. The acquisition of ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... , SAN MATEO, Calif., Aug. 25 ... focused on developing and commercializing novel pain management therapies, today announced ... as a director and Audit Committee chairman, effective August 20, 2009. ... a company focused on exploiting a novel, Nobel Prize winning method ...
... Aug. 25 Repligen Corporation (Nasdaq: RGEN ... been elected to its Board of Directors. Dr. ... biotechnology industries with expertise in transforming development stage companies ... Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., ...
... , , SYDNEY, Aug. 25 ... global meltdown. By 2020 the government envisages this sector will employ up to ... Malaysia ,s GDP. , , (Logo: ... impact on the Malaysian economy has highlighted the need for Malaysia to focus ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors 2Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors 3Malaysian Biotechnology Sector 2Malaysian Biotechnology Sector 3Malaysian Biotechnology Sector 4
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... comprehensive look at market competition between wild and farmed ... issues surrounding farmed and wild salmon. , The ... released by TRAFFIC, the wildlife trade monitoring network of ... two important trends that have remade the salmon industry ...
... stem cells derived from muscle have a greater ability to ... study at Children’s Hospital of Pittsburgh of UPMC. , The ... of the Journal of Cell Biology, is the first ever ... cells based on sex. , This finding could have ...
... edition of the Proceedings of the National Academy of Sciences ... provides new evidence that Nod1, a member of the Nod-like ... which also activates Resistance (R) proteins in plants; R proteins ... similarities between the Nod1 protein, which plays a pivotal role ...
Cached Biology News:New report: Explosive growth changes salmon industry 2The sturdier sex? -- Study by Pittsburgh scientists finds female stem cells work better 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3
... White to off-white solid. Increases the expression of ... Soluble in H 2 O. Unstable in ... RTECS EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... L., and Junod, A.F. 1995. Biochem. J. ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: